|
CD164 expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 8.62319993188976E-10 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
2.91560000031943E-07 |
| Normal-vs-Stage2 |
2.104600E-03 |
| Normal-vs-Stage3 |
4.88498130835069E-15 |
| Normal-vs-Stage4 |
2.7077007302978E-11 |
| Stage1-vs-Stage2 |
4.017600E-01 |
| Stage1-vs-Stage3 |
4.640900E-04 |
| Stage1-vs-Stage4 |
2.104800E-03 |
| Stage2-vs-Stage3 |
8.601700E-03 |
| Stage2-vs-Stage4 |
6.978600E-03 |
| Stage3-vs-Stage4 |
6.311600E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
3.5527136788005E-15 |
| Normal-vs-AfricanAmerican |
1.195760E-02 |
| Normal-vs-Asian |
1.50619999805812E-08 |
| Caucasian-vs-AfricanAmerican |
4.104200E-01 |
| Caucasian-vs-Asian |
6.669400E-01 |
| AfricanAmerican-vs-Asian |
5.502400E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.28630003817898E-09 |
| Normal-vs-Female |
6.48069997666312E-09 |
| Male-vs-Female |
3.806200E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
2.47050000012905E-07 |
| Normal-vs-Age(41-60Yrs) |
5.95159477256857E-11 |
| Normal-vs-Age(61-80Yrs) |
1.17370000385364E-08 |
| Normal-vs-Age(81-100Yrs) |
8.15560000000382E-05 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
1.329980E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
3.826200E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
1.597150E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
6.928400E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.037200E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
2.456000E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
1.600760E-04 |
| Classical-VS-Follicular |
4.25079999999411E-06 |
| Classical-VS-Other |
5.518000E-01 |
| Classical-VS-Normal |
1.78179693222091E-12 |
| Tall-VS-Follicular |
5.22660026369692E-10 |
| Tall-VS-Other |
3.260600E-03 |
| Tall-VS-Normal |
8.99280649946377E-15 |
| Follicular-VS-Other |
2.295700E-02 |
| Follicular-VS-Normal |
1.586390E-01 |
| Other-VS-Normal |
9.390200E-04 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
4.41760000025049E-07 |
| Normal-vs-N1 |
2.56095145090285E-12 |
| N0-vs-N1 |
3.350700E-04 |
|
|
